Highlights Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
40.15 ^USD	-1.08%		-6.65%	+22.56%

Feb. 23	Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating	MT
Feb. 20	Top Midday Gainers	MT

Highlights

Feb. 19	Spyre Therapeutics Q4 Loss Narrows, Cash Runway Expected Into Q2 2028	MT
Feb. 19	Earnings Flash (SYRE) Spyre Therapeutics Posts Q4 Loss $-0.70, vs. FactSet Est of Loss of $-0.71	MT
Feb. 19	Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Nov. 04	Spyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 04	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended Anti-IL-23 Antibody	CI
25-10-15	Spyre Therapeutics Closes $316.2 Million Public Offering	MT
25-10-14	Spyre Therapeutics Prices $275 Million Share Offering	MT
25-10-13	Spyre Therapeutics announces pricing of $275 million public offering of common stock	RE
25-10-13	Spyre Therapeutics Launches Public Offering	MT
25-09-15	Spyre Therapeutics, Inc. Doses First Patient in Pioneering Phase 2 SKYway Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases	CI
25-08-05	Spyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-17	Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts	CI
25-05-08	Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-05	Spyre Therapeutics, Inc. Announces Poster Presentations at Digestive Disease Week 2025 Including Up to Eight Months of Follow-Up from an Ongoing Phase 1 Trial of SPY001	CI
25-03-27	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of Spy003, Its Novel Half-Life Extended Il-23 Antibody	CI
25-02-27	Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25-02-27	Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
24-12-11	JonesTrading Initiates Spyre Therapeutics at Hold	MT
24-12-02	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies	CI
24-11-19	Spyre Therapeutics Prices $200 Million Common Stock Offering	MT
24-11-18	Spyre Therapeutics Launching Public Offering of Shares, Warrants	MT
24-11-12	Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Data from its First-In-Human Trial of SPY001	CI
24-11-07	Spyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-09-06	Spyre Therapeutics Files $500 Million Mixed Securities Shelf	MT
24-09-04	Wedbush Initiates Spyre Therapeutics at Outperform With $45 Price Target	MT